An interventional study of Dietetic support and Continuous glucose monitoring in Type 2 Diabetes Mellitus (T2DM), Continuous Glucose Measurement and Dietary Modification, sponsored by Australian Catholic University. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Australian Catholic University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 262 studies in Diabetes Mellitus, Type 2 with a site in Australia — 24 open to participants now, 30 under way, 13 of them phase 3. Diabetes Mellitus, Type 2 · Australia.
Among the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, this one is the 174th largest by enrollment of the 246 interventional ones that give a count, is one of 9 that started in 2025, is one of 31 with no phase, reaches primary completion later than 7 of the 29 other live ones, and was the 238th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →24 of the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Australia, United States, Canada and 3 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Bulgaria and 10 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 12 more countries
Ages 18+
Novo Nordisk A/S · Sites in Australia, United States, Germany and 6 more countries
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
262 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 47 · Phase 3 136 · Phase 4 22
First in 2001; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 392 across the 246 interventional studies, 911 across the 16 observational. Of the 224 that completed or were terminated, 115 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
223 of 262 have an industry lead sponsor. The 10 most frequent:
Australian Catholic University is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Australian Catholic University has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
9 of the studies in Diabetes Mellitus, Type 2 with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06888687Australian Catholic UniversityComparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes. | 2026-11-28 |
| NCT07228117Medtronic MiniMed, Inc.GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | 2027-01 |
| NCT06937203Arrowhead PharmaceuticalsA First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | 2027-02 |
| NCT06267391Endogenex, Inc.Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | 2027-02-01 |
| NCT07215559Eli Lilly and CompanyA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | 2027-03 |
Add all 9 to your calendar (.ics) → With an account.
Among the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with type 2 diabetes, by researchers from Australian Catholic University, University of Adelaide, University of Queensland, University of Wollongong, Monash University, Monash Partners, Deakin University, La Trobe University and Melbourne University.
In a parallel groups design, a total of 156 individuals will be recruited. After baseline pathology (HbA1c), blinded (Libre Pro iQ) continuous glucose monitoring (CGM) data and questionnaires (via REDCap) have been collected, participants will be randomised into one of two groups (DIET, dietetic support only; CGMD, CGM plus dietetic support). All participants will receive four (4) dietetic consults via telehealth at weeks 2, 6, 10 and 16, the content of which will be related to the randomised condition. Measurements will be repeated at 3 and 6 months from baseline to assess the changes in primary and secondary outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence.
Behavioral: Dietetic support
The CGM plus dietetic support group will be provided 'standard care' dietetic support alongside the use, and interpretation of, the CGM data collected to assist in the understanding of dietary modifications on glucose management. As per the DIET group, dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. The CGM data collected via LibreLink will be used by both the participant and the dietitian to inform dietary modifications.
Behavioral: Dietetic support · Device: Continuous glucose monitoring
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence.
Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor. Nine sensors will be provided for the 6-month period, for 3 months of continuous use and 3 months of intermittent (2 weeks on - 2 weeks off) use.
HbA1c
Glycated haemoglobin concentration
Time frame: baseline, 6 months
HbA1c
Glycated haemoglobin concentration
Time frame: 3 months
24 h assessment of glycaemia
24 h glucose measures assessed by blinded CGM (including, but not limited to, time in range, CV)
Time frame: baseline, 6 months
CGM application and use
number of days of CGM use and interaction with viewing CGM data (via LibreLink); CGMD group ony
Time frame: From 0 to 26 weeks, per 2 week period of sensor use
Per protocol analysis
Primary analysis of the primary outcome (0-6 months HbA1c) is going to be intention to treat. Therefore, secondary analysis of all other variables will be a per-protocol (PP) analysis. Inclusion in PP analysis will be defined by: 1\. Attendance at ≥3 dietetic consults, within ±10 days of the designated 2-, 6-, 10- and 16-week time points.
Time frame: 6 months
Dietary intake
energy and macronutrient composition calculated from food records
Time frame: baseline, 3 months, 6 months
Fasting blood glucose
fasting blood glucose concentrations
Time frame: baseline, 3 months, 6 months
Adherence
measures of adherence assessed by self-report (questionnaire)
Time frame: baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks
hs-CRP
fasting high sensitive C-Peptide concentrations
Time frame: baseline, 3 months, 6 months
Fasting cholesterol
Fasting cholesterol concentrations (total, HDL and LDL)
Time frame: baseline, 3 months, 6 months
Fasting lipid concentration
fasting triglyceride concentrations
Time frame: baseline, 3 months, 6 months
Medication effect score (MES)
Medication effect score for antihyperglycemic medications
Time frame: baseline, 6 months
Participant experience
Qualitative semi-structured interviews
Time frame: 6 months
Physical activity
Self-reported questionnaire (International Physical Activity Questionnaire (IPAQ) - Long Form)
Time frame: baseline, 3 months, 6 months
Sleep quality and quantity
Self-reported questionnaire (Pittsburgh Sleep Quality Index (PSQI))
Time frame: baseline, 3 months, 6 months
Eating behaviours
Self-reported questionnaire (Eating Disorders Examination Questionnaire (EDEQ))
Time frame: baseline, 3 months, 6 months
Health literacy
self-reported questionnaire (Health Literacy Questionnaire (HLQ))
Time frame: baseline, 3 months, 6 months
Dietary quality
Assessed using the Healthy Eating Index For Australian adults (HEIFA)
Time frame: baseline, 3 months, 6 months
Diabetes self-management
Self-reported questionnaire (Diabetes Self-Management Questionnaire (DSMQ-R))
Time frame: baseline, 3 months, 6 months
Diabetes distress
Self-reported questionnaire (Type 2 Diabetes Distress Assessment Scale (T2DDAS))
Time frame: baseline, 3 months, 6 months
Overall well-being
Self-reported questionnaire (WHO-5)
Time frame: baseline, 3 months, 6 months
Diabetes-specific well-being
Self-reported questionnaire (DAWN Impact of Diabetes Profile (DIDP-7))
Time frame: baseline, 3 months, 6 months
Treatment satisfaction
self-reported questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQs (status) and DTSQc (change)))
Time frame: baseline, 3 months, 6 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publicly available, as it contains information that could compromise research participant consent.
Supporting information: Study protocol
Access criteria: Reasonable requests of data for academic use will be considered. Requests can be made to the corresponding author of the publication. Data will not be made publicly available as it contains information that could compromise research participant consent.
Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 18 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Australian Catholic University